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Abstract
Guanylin and uroguanylin are small cysteine-rich peptides involved in the regulation of fluid and electrolyte home-
ostasis through binding and activation of guanylyl cyclases signaling molecules expressed in intestine and kidney. 
Guanylin is less potent than uroguanylin as a natriuretic agent and is degraded in vitro by chymotrypsin due to unique 
structural features in the bioactive moiety of the peptide. Thus, the aim of this study was to verify whether or not gua-
nylin is degraded by chymotrypsin-like proteases present in the kidney brush-border membranes. The isolated perfused 
rat kidney assay was used in this regard. Guanylin (0.2 µM) induced no changes in kidney function. However, when 
pretreated by the black-eyed pea trypsin and chymotrypsin inhibitor (BTCI - 1.0 µM; guanylin - 0.2 µM) it promoted 
increases in urine flow (ΔUF of 0.25 ± 0.09 mL.g-1/min, P < 0.05) and Na+ excretion (% Δ ENa+ of 18.20 ± 2.17, 
P < 0.05). BTCI (1.0 µM) also increased %ENa+ (from 22.8 ± 1.30 to 34.4 ± 3.48, P < 0.05, 90 minutes). Furthermore, 
BTCI (3.0 µM) induced increases in glomerular filtration rate (GFR; from 0.96 ± 0.02 to 1.28 ± 0.02 mL.g-1/min, 
P < 0.05, 60 minutes). The present paper strongly suggests that chymotrypsin-like proteases play a role in renal me-
tabolism of guanylin and describes for the first time renal effects induced by a member of the Bowman-Birk family of 
protease inhibitors.
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BTCI aumenta a natirurese induzida por guanilina e promove  
efeitos renais glomerulares e tubulares
Resumo
Guanilina e uroguanilina são peptídeos pequenos, ricos em cisteína, envolvidos na regulação da homeostase de fluidos 
e eletrólitos através da ligação e ativação da guanilato ciclase expressa no intestino e nos rins. A guanilina é menos 
potente do que a uroguanilina como agente natriurético e é degradada in vitro pela quimiotripsina devido a caracterís-
ticas estruturais únicas no domínio bioativo do peptídeo. Portanto o objetivo deste trabalho foi verificar se a guanilina 
é degradada por proteases tipo quimiotripsina, presentes na membrana da borda em escova dos rins. Para esta investi-
gação, foi usado o modelo do rim isolado de rato perfundido. A Guanilina (0,2 µM) não induziu mudanças na função 
renal. Entretanto, quando pré-tratada com inibidor de tripsina e de quimiotripsina de black-eyed pea (BTCI - 1,0 µM; 
guanilina - 0,2 µM) promoveu um aumento no fluxo urinário (ΔUF de 0,25 ± 0,09 mL.g–1/min, P < 0,05) e na excreção 
de Na+ (%ΔENa+ de 18,20 ± 2,17, P < 0,05). BTCI (1,0 µM) também aumenta %ENa+ (de 22,8 ± 1,30 a 34,4 ± 3,48, 
P < 0,0590 minutos). Além disto, BTCI (3,0 µM) induziu um aumento da taxa de filtração glomerular (GFR; de 
0,96 ± 0,02 para 1,28 ± 0,02 mL.g–1/min, P < 0,05, 60 minutos). O presente trabalho sugere fortemente que proteases 
semelhantes à quimiotripsina desempenham um papel no metabolismo renal de guanilinas e descreve, pela primeira 
vez, os efeitos renais induzidos por um membro da família de inibidores de proteases do tipo Bowman-Birk.
Palavras-chave: natriurese, rim, Inibidores de proteases tipo Bowman-Birk, BTCI, GMP cíclico, Vignia unguiculata.
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1. Introduction
Several heat-stable peptides produced by enter-
opathogenic bacteria are capable of inducing intestinal 
secretion via the intracellular second messenger, cyclic 
GMP (Hughes et al., 1978). The most extensively stud-
ied of these peptides is the E. Coli (Theodor Escherich, 
1885) heat-stable enterotoxin (STa). The intestinal re-
ceptor for STa has been cloned and shown to belong to 
the family of particulate guanylyl cyclases (pGCs), and 
was named guanylate cyclase C (GC-C) (Schulz et al., 
1990). STa also induces natriuresis and kaliuresis in the 
isolated perfused rat kidney (Lima et al., 1992). This 
action is mimicked by 8-Br-cGMP (Lima et al., 1992). 
Potential receptors bind selectively to I125 – STa in sev-
eral epithelia of the North American opossum, includ-
ing the kidney (Forte et al., 1989).
Two endogenous peptides that share strong structural 
homology to STa were initially isolated from rat jejunum 
and opossum urine, and named guanylin and uroguany-
lin, respectively (Currie et al.,1992; Hamra et al., 1993). 
Both peptides activate the same signaling pathway of 
STa and also induce intestinal fluid and chloride secre-
tion, as reviewed by Forte et al. (2000). In the isolated 
perfused rat kidney, both peptides elicit strong natriuretic 
and kaliuretic responses (Fonteles et al., 1998). Thus, 
guanylin and uroguanylin may influence kidney function 
via some physiological interactions involving the intra-
cellular second messenger cGMP. A kidney guanylyl 
cyclase activated by guanylin/STa peptides was recently 
cloned from opossum kidney (OK) cells and named OK-
GC (London et al., 1999).
Greenberg and colleagues have demonstrated that 
guanylin but not uroguanylin is degraded in vitro by 
chymotrypsin (Greenberg et al., 1997). The poten-
tial explanation for this observation lies in the fact 
that guanylin has aromatic amino acids in its bioac-
tive form (either phenylalanine or tyrosine, depending 
on the animal from which the peptides were isolated) 
and this structural feature makes it prone to cleavage 
by chymotrypsin (Forte et al., 2000, Greenberg et al., 
1997).
The aim of this study was to investigate whether or 
not chymotrypsin-like proteases play a role in renal me-
tabolism of guanylin. BTCI, a Bowman-Birk type pro-
tease inhibitor isolated from V. unguiculata (Linnaeus) 
Walpers, 1842 (cv Seridó) seeds was used as a pharma-
cological tool to test this hypothesis (Morhy and Ventura, 
1987). BTCI is a stable globular protein whose complete 
primary sequence was determined by Morhy and Ventura 
(Morhy and Ventura, 1987). It contains a single polypep-
tide chain of 83 residues, including 14 half cysteines 
(Morhy and Ventura, 1987). The three dimensional model 
of the BTCI-α-chymotrypsin complex has been recently 
developed (Freitas et al., 1997). BTCI contain two inde-
pendent reactive sites that interact simultaneously with 
trypsin and chymotrypsin. Phe-43 is the key amino acid 
in the chymotrypsin reactive site and is located in the tip 
of a β–hairpin (Freitas et al., 1997).
2. Materials and Methods
Rat Guanylin (PNTCEICAYAACTGC - mol wt 1516) 
was synthesized by a solid-phase method and purified as 
described in detail elsewhere (Currie et al., 1992). BTCI 
was extracted from dry seeds and purified according to 
procedures described in previous papers (Ventura and 
Xavier-Filho, 1966). The protein was verified to be ho-
mogeneous by polyacrylamide gel electrophoresis, SDS-
polyacrylamide gel electrophoresis and electrofocusing, 
as previously described (Ventura and Xavier-Filho, 
1966). All chemicals were reagent grade and purchased 
from either Sigma (St. Louis, MO), Merck (West Point, 
PA) or American Peptide Corporation.
Adult Wistar-Kyoto rats from either sex weigh-
ing 250-300 g had tap water ad libitum, were fasted 
overnight and anesthetized with sodium pentobarbital 
( 50 mg .kg-1, i.p.). The right kidney was perfused with 
a modified Krebs-Henseleit solution (MKHS) contain-
ing albumin (6 g%) for 120 minutes as control (n = 12), 
according to experimental procedures described in de-
tail by Fonteles et al. (1983). At 10 minutes intervals 
aliquots of both urine and perfusate were collected and 
analyzed for inulin by the method previously described 
by Wasler as modified by Fonteles and others (Fonteles 
et al., 1983; Wasler et al., 1955). Electrolytes were 
measured by flame photometry. Osmolality of the sam-
ples was determined in Advanced Instruments osmom-
eter (Needham Heights, MA). Glomerular filtration 
rate (GFR), perfusion pressure (PP), urine flow (UF), 
as well as the fractional excretion of Na+ (%ENa+) and 
K+ (%EK+) were determined at 10 minutes intervals 
using the conventional clearance formula (Martinez-
Maldonato and Opava-Stitzer, 1978).
In the first experimental group, guanylin-only-treated 
group, guanylin (0.2 µM) was added to perfusate reser-
voir after a 30 minutes internal control period and func-
tional observations were made for 90 minutes. In the other 
group after 30 minutes of perfusion with BTCI (1.0 µM), 
guanylin (0.2 µM) was added to perfusate and experi-
mental observations were made for the next 90 minutes. 
In the BTCI-only-treated group, BTCI (0.3-3.0 µM) was 
added to perfusate reservoir after a 30 minutes internal 
control. In the control experiments the kidneys were per-
fused with MKHS for 120 minutes.
The data were averaged in triplicates at 30 minutes 
intervals and statistical analysis was carried out by 
one-way ANOVA and Student’s t-test when applicable. 
In order to avoid the influence of individual variations 
between animals used in this study and to differenti-
ate the effects of BTCI and guanylin, comparisons be-
tween various experimental groups were made based 
in the variation (Δ) of each group at 30 minutes inter-
vals. Due to the same reasons mentioned above, the 
renal effects of BTCI were presented in this paper in 
absolute values compared with the 30 minutes inter-
nal control period of each group. Data are presented 
as means ± SEM. There were at least four perfused 
kidneys for each data point.
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Table 1. Data from control kidneys perfused with Krebs-Henseleit solution containing albumin (6g%) and kidneys treated 
with BTCI (0.3-3.0 µM).
UF(mL.g-1/min) 30 minutes 60 minutes 90 minutes 120 minutes
Control 0.15 ± 0.02 0.17 ± 0.02 0.17 ± 0.02 0.17 ± 0.02
BTCI 0.3 µM 0.21 ± 0.02 0.26 ± 0.02 0.24 ± 0.01 0.28 ± 0.02*
BTCI 1.0 µM 0.13 ± 0.01 0.26 ± 0.02* 0.20 ± 0.01 0.17 ± 0.01
BTCI 3.0 µM 0.24 ± 0.02 0.28 ± 0.01 0.26 ± 0.01 0.26 ± 0.01
GFR(mL.g-1/min) 30 minutes 60 minutes 90 minutes 120 minutes
Control 0.69 ± 0.09 0.66 ± 0.09 0.65 ± 0.09 0.65 ± 0.09
BTCI 0.3 µM 0.86 ± 0.10 0.90 ± 0.09 0.97 ± 0.02* 0.87 ± 0.04
BTCI 1.0 µM 0.59 ± 0.06 0.75 ± 0.07* 0.51 ± 0.07 0.47 ± 0.05
BTCI 3.0 µM 0.96 ± 0.02 0.75 ± 0.07* 1.00 ± 0.06 1.07 ± 0.07
PP(mmHg) 30 minutes 60 minutes 90 minutes 120 minutes
Control 122.1 ± 3.17 122.3 ± 3.40 120.3 ± 2.27 121.8 ± 3.62
BTCI 0.3 µM 118.7 ± 1.42 114.8 ± 3.25 120.8 ± 7.00 120.0 ± 4.64
BTCI 1.0 µM 110.0 ± 2.28 139.0 ± 4.98* 129.0 ± 6.36 122.0 ± 6.31
BTCI 3.0 µM 110.1 ± 1.66 122.1 ± 2.96* 138.1 ± 0.88* 151.1 ± 2.08*
%ENa+ 30 minutes 60 minutes 90 minutes 120 minutes
Control 20.6 ± 1.31 19.8 ± 1.37 20.2 ± 1.37 19.7 ± 1.37
BTCI 0.3 µM 22.7 ± 0.68 26.7 ± 2.30 23.0 ± 2.51 30.0 ± 2.84*
BTCI 1.0 µM 22.8 ± 1.30 32.9 ± 1.99 34.4 ± 2.80* 31.8 ± 4.28*
BTCI 3.0 µM 24.8 ± 1.20 20.9 ± 1.12 23.8 ± 0.67 21.4 ± 0.37
%EK+ 30 minutes 60 minutes 90 minutes 120 minutes
Control 30.0 ± 2.56 25.4 ± 2.56 24.6 ± 2.56 24.7 ± 2.56
BTCI 0.3 µM 35.5 ± 2.84 48.8 ± 6.29* 49.3 ± 9.10 40.7 ± 3.95
BTCI 1.0 µM 43.2 ± 3.19 55.2 ± 5.70 65.7 ± 9.67* 58.5 ± 8.94*
BTCI 3.0 µM 32.9 ± 1.31 29.3 ± 1.86 37.7 ± 0.93 35.3 ± 0.71
Cosm(mL.g-1/min) 30 minutes 60 minutes 90 minutes 120 minutes
Control 0.13 ± 0.02 0.13 ± 0.02 0.14 ± 0.02 0.13 ± 0.02
BTCI 0.3 µM 0.21 ± 0.02 0.25 ± 0.02 0.22 ± 0.01 0.26 ± 0.02
BTCI 1.0 µM 0.13 ± 0.02 0.23 ± 0.01* 0.17 ± 0.01 0.14 ± 0.09
BTCI 3.0 µM 0.25 ± 0.04 0.28 ± 0.01 0.25 ± 0.01 0.24 ± 0.02
a) GFR, PP, Cosm, %EK+, %ENa+ and UF are glomerular filtration rate, perfusion pressure, osmolar clearance, fractional 
excretion of potassium, fractional excretion of sodium and urine flow, respectively;
b) *P < 0.05, compared to the 30 minutes internal control of the respective group (ANOVA and Student’s t-test).
3. Results
The isolated perfused rat kidney control experiments 
were always very stable. Once placed in perfusate solu-
tion, after a 15 minutes equilibration period, all function-
al parameters remain stable throughout the experimental 
period (Table 1 and Figure 1).
Dose-response experiments suggested that BTCI 
was capable of inducing changes in renal function. 
Thus, BTCI (0.3-3.0 µM) was evaluated for the abil-
ity to influence ex vivo renal function. BTCI even at 
the smallest concentration tested in this study pro-
moted increases in %ENa+ (from 22.7 ± 0.68% to 
30.0 ± 2.84%, P < 0.05, 120 minutes). However, in the 
range of concentrations tested in this study this effect 
was not dose-dependent (Table 1). Furthermore, BTCI 
(3.0 µM) also promoted a sharp increase in PP (from 
110.1 ± 1.66 mmHg to 151.8 ± 2.08 mmHg, 120 min-
utes, P < 0.05). BTCI (1.0 µM) promoted a strong but 
transient diuretic response (UF; from 0.13 ± 0.01 mL.g-1/
min to 0.26 ± 0.02  mL.g-1 / min, P < 0.05). An increase 
in %EK+ was also observed (from 43.2 ± 3.19% to 
65.7 ± 9.67%, P < 0.05, 90 minutes, 1.0 µM). Moreover, 
BTCI (3.0 µM) produced a large increase in GFR (from 
0.96 ± 0.02 mL.g-1/min to 1.28 ± 0.02  mL.g-1 / min, 60 min-
utes, P < 0.05). An increase in Cosm (BTCI-3.0 µM) was 
also observed (from 0.13 ± 0.02 mL.g-1/min to 0.23 ± 0.01 
mLg-1/min, P < 0.05, 60 minutes). Thus, in the range of 
concentrations tested, BTCI influenced many functional 
parameters determined in the present study.
On the other hand, guanylin (0.2 µM) produced no 
effects on kidney function (Figure 1). These results are 
in agreement to previous data obtained by Fonteles et al. 
(1998) using this bioassay.
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Discussion
Both proguanylin and uroguanylin/prouroguanylin 
levels are markedly increased in chronic renal failure 
(Nakazato et al., 1996). Noteworthy is the fact that this 
increase positively correlates with the magnitude of the 
decrease in the renal functioning mass (Nakazato et al., 
1996). Thus, the kidney appears to play an important role 
in clearing guanylin from plasma.
In general, polypeptide hormones are removed from 
the renal circulation by two pathways (Rabkin and Kitaji 
1983). The predominant pathway is glomerular filtra-
tion, which is followed by proximal tubular degradation. 
Depending on the structure of the peptide, hydrolysis 
proceeds either after contact with the brush-border mem-
brane or after internalization, for complex peptides in a 
non-filtering pathway. Since BTCI is a medium size pro-
tein, it must be filtered by the glomerulus. However, we 
can not demonstrate what type of pathway predominates 
in guanylin metabolism. Guanylin is a small (15 amino 
acid) linear peptide, suggesting that the brush-border 
proteases may play a major role in guanylin renal me-
tabolism. Therefore, proguanylin which is the main form 
of guanylin found in plasma (Forte et al., 2000) may 
undergo degradation by chymotrypsin-like proteases 
present in renal brush-border membranes. This in turn 
may explain the fact that guanylin is found only at a low-
to-non-detectable levels in mammalian urine.
The fact that guanylin undergoes renal metabolism 
and that BTCI enhanced guanylin-induced natriuresis 
may explain the observation made by Fonteles et al. 
(1998) that uroguanylin is more potent than guanylin as 
a natriuretic peptide in the isolated perfused rat kidney. 
Greenberg and coworkers (1997) also demonstrated that 
uroguanylin induces a much higher increase in natriure-
sis in the in vivo urethra-sealed mouse model.
Despite the fact that circulating proguanylin levels 
greatly exceed the plasma levels of both uroguanylin and 
prouroguanylin, uroguanylin is the only biologically ac-
tive peptide found in mammalian urine at appreciable 
concentrations as reviewed by Forte et al. (2000). This 
finding is a strong evidence that guanylin undergoes re-
nal metabolism after glomerular filtration.
Uroguanylin instead of guanylin has been implicated 
as an intestinal natriuretic hormone as reviewed by Forte 
et al. (2000). One of the main reasons for this speculation 
is the fact that guanylin has not been easily isolated from 
mammalian urine, possibly because this peptide is fully 
degraded by renal proteases. Several pieces of evidence 
suggest that guanylin peptides produced within the kid-
ney may participate in the complex array of physiologi-
cal mediators that ensure salt balance in postprandial 
states (Forte et al., 2000; Potthast et al., 2001). 
Evidence for this theory comprises the fact that 
plasma guanylin increases in parallel to the degree of 
renal dysfunction and 125I-labeled guanylin accumulates 
in the kidney what may indicate reduced guanylin renal 
metabolism (Date et al., 1996). Moreover, oral admin-























































































Control Guanylin (0.2 MM) BTCI (1.0 MM) 
Guanylin (0.2 MM) + BTCI (1.0 MM) * p < 0.05
Figure 1. Variation of the fractional Na+ excretion 
(Δ%ENa+), urine flow (ΔUF) and osmolar clerance 
(ΔCosm) changes promoted by guanylin, BTCI and gua-
nylin plus BTCI in kidneys perfused with modified Krebs-
Henseleit solution at the concentrations shown in the leg-
end. P < 0.05, compared with all other groups at the same 
time (ANOVA and Student’s t-test). Δt1, Δt2 and Δt3 are 
30 minutes experimental periods where functional observa-
tions were made within each group and then compared. See 
text for further details.
BTCI pretreatment promoted a significant increment 
in the variation of fractional Na+ excretion induced by gua-
nylin at subthreshold concentrations that was independ-
ent of its intrinsic effects (Δ%ENa+ of 18.20 ± 2.17%, 
Δt3, P < 0.05, compared with all other groups; Figure 1). 
A parallel increase in urine flow was also observed 
in guanylin-perfused after BTCI exposure (ΔUF of 
0.25 ± 0.09 mL.g-1/min, P < 0.05; Δ t3 Figure 1). BTCI 
plus guanylin also induced an overwhelming increase in 
osmolar clearance (ΔCosm of 0.23 ± 0.08  mL.g-1/min, 
P < 0.05, Δt3; Figure 1). An increase in GRF was also 
verified (data not shown).
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intestine using the suckling mice as model but this is 
only achieved with guanylin when administered together 
with a protease inhibitor. Moreover, relatively high con-
centrations of bioactive uroguanylin were found in the 
urine of opossums, rats and humans in contrast to the 
low to undetectable levels of guanylin in the same spe-
cies (Hamra et al., 1993; Kita et al., 1994; Hamra et al., 
1996a; 1996b). Since proguanylin can be detected in 
plasma (Kuhn et al., 1993; Nakazato et al., 1994) and 
its mRNA can be identified in the kidney (Schulz et al., 
1992) the very low level of guanylin in urine may be due 
to the degradation of guanylin by renal chymotripsin-
like proteases in the renal tubules. Renal metabolism of 
this peptide may also explain why uroguanylin is more 
potent as natriuretic and kaliuretic than guanylin in the 
isolated perfused rat kidney (Fonteles et al., 1998). 
The heat-stable enterotoxin from E. coli (STa) is 
referred as a long-lived GC-C superagonist and causes 
natriuresis and kaliuresis in the isolated perfused kidney 
(Lima et al., 1992). The tyrosine-alanine segment present 
at residue 9 in the sequence of guanylin is the only site 
absent in Sta and represents a potential chymotryptic 
site. This theory is reinforced by the fact that the replace-
ment of tyrosine-alanine with asparagine-proline at that 
residue in the sequence of guanylin turns it resistant to 
protease (Carpick and Gariépy, 1993) and the blockade 
of guanylin degradation by another chymotrypsin inhibi-
tor named chymostatin (Santos-Neto et al., 2003).
The present paper also describes for the first time in the 
literature renal functional effects of a Bowman-Birk pro-
tease inhibitor. Both amino acid sequencing and 3-D spa-
tial modeling have demonstrated that BTCI share strong 
structural homology with other members of the Bowman-
Birk family of protease inhibitors. Thus, whether or not 
other members of the Bowman-Birk family of proteinase 
inhibitors exhibit renal effects is a question to be argued. 
Therefore, this hypothesis awaits further investigation. 
BTCI may also inhibit the degradation of some peptide 
mediators, including native guanylin that are constitutive-
ly produced by the kidney as demonstrated by Northern 
analysis and/or RT-PCR (Potthast et al., 2001; Carrithers 
et al., 2000), and this, in turn, may play a contributory role 
for some of the effects herein described.
Studies are currently underway in our laboratories to 
characterize the mechanisms of action of the renal ef-
fects of BTCI described in the present study as well as to 
identify the possible participation of other renal enzymes 
in the metabolism of guanylin.
The present work provides experimental evidence 
that supports the speculation showed in the literature that 
chymotrypsin-like protease found on kidney tubules may 
play a role in cleavage and inactivation of guanylin.
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